RET fusion-positive cancers

GPTKB entity

Predicate	Object
gptkbp:instanceOf	cancer subtype
gptkbp:alternativeName	RET fusion-driven cancers RET-positive cancers RET-rearranged cancers
gptkbp:approvalYear	2020 (pralsetinib) 2020 (selpercatinib)
gptkbp:associatedWith	gptkb:RET_proto-oncogene
gptkbp:clinicalTrialPhase	ARROW LIBRETTO-001
gptkbp:diagnosedBy	gptkb:reverse_transcription_PCR gptkb:fluorescence_in_situ_hybridization next-generation sequencing
gptkbp:FDAApproved	gptkb:pralsetinib gptkb:selpercatinib
gptkbp:hasBiomarker	gptkb:RET_fusion
gptkbp:hasCommonFusionPartner	gptkb:CCDC6 gptkb:KIF5B gptkb:NCOA4
gptkbp:hasGuidelineRecommendation	gptkb:NCCN_guidelines ESMO guidelines
gptkbp:hasMolecularAlteration	gptkb:RET_gene_fusion
gptkbp:hasMolecularTestingRecommendation	all advanced NSCLC patients all advanced thyroid cancer patients
gptkbp:hasOncogenicDriver	gptkb:RET_fusion
gptkbp:hasPathogenesis	constitutive activation of RET kinase
gptkbp:hasPrevalenceInNSCLC	1-2%
gptkbp:hasPrevalenceInThyroidCancer	10-20%
gptkbp:hasResistanceMechanism	MET amplification secondary RET mutations
gptkbp:hasTreatmentOption	chemotherapy immunotherapy targeted therapy
https://www.w3.org/2000/01/rdf-schema#label	RET fusion-positive cancers
gptkbp:ICD-10_code	C34 (for lung) C73 (for thyroid)
gptkbp:occurredIn	gptkb:non-small_cell_lung_cancer gptkb:papillary_thyroid_carcinoma gptkb:cancer gptkb:medullary_thyroid_carcinoma
gptkbp:prevalence	rare
gptkbp:prognosis	variable
gptkbp:target	gptkb:pralsetinib gptkb:selpercatinib
gptkbp:bfsParent	gptkb:Gavreto gptkb:Pralsetinib
gptkbp:bfsLayer	7